D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $18.00 price target on the stock. D. Boral Capital’s price target suggests a potential upside of 174.39% from the company’s current price.

Separately, Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday, March 20th.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $6.56 on Thursday. The stock has a market capitalization of $109.72 million, a P/E ratio of -10.09 and a beta of 0.31. Coya Therapeutics has a one year low of $4.75 and a one year high of $10.24. The firm’s 50 day simple moving average is $6.43 and its two-hundred day simple moving average is $6.51.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. As a group, equities analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its position in shares of Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after acquiring an additional 4,777 shares in the last quarter. XTX Topco Ltd purchased a new stake in Coya Therapeutics in the fourth quarter worth $59,000. Jane Street Group LLC purchased a new stake in Coya Therapeutics in the fourth quarter worth $74,000. Northern Trust Corp raised its holdings in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after purchasing an additional 3,099 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new position in Coya Therapeutics during the fourth quarter valued at $401,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.